Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kairos Pharma, Ltd. Common Stock (NY: KAPA )

1.370 -0.080 (-5.52%)
Official Closing Price Updated: 8:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kairos Pharma, Ltd. Common Stock

BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Adds Huntsman Cancer Institute to Phase 2 Trial for Prostate Cancer Therapy
Via Investor Brand Network
Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Preclinical Data on GITR Agonist KROS 101 at AACR-JCA Conference
Via Investor Brand Network
Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma
From Kairos Pharma, Ltd.
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at AACR-JCA Joint Conference on Innovative Cancer Therapy
Via Investor Brand Network
Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2024 Milestones and 2025 Clinical Outlook
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Kairos Pharma Provides Business Update and Outlook into 2025
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Present at Lytham Partners Investor Healthcare Summit
Via Investor Brand Network
Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – EF Hutton Provided ‘Buy’ Rating, $9.00 Price Target in Kairos Pharma, Ltd. (NYSE: KAPA) Recent Research Report
Via Investor Brand Network
BioMedNewsBreaks — Kairos Pharma, Ltd. (NYSE: KAPA) Receives ‘Buy’ Recommendation, $12.00 Price Target in Rodman & Renshaw Research Report
Via Investor Brand Network
Kairos Pharma to Participate in The Microcap Conference in January 2025
Via ACCESSWIRE
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present Growth Strategy at The Microcap Conference 2025
Via Investor Brand Network
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Expands Phase 2 Trial of ENV105 to City of Hope for Prostate Cancer Therapy
Via Investor Brand Network
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
From Kairos Pharma, Ltd
Via Business Wire
InvestorkNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Engages IBN for Corporate Communications Expertise
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Kairos Pharma Ltd. (NYSE: KAPA) Developing Innovative Therapies to Tackle Cancer Drug Resistance, Immune Suppression
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Kairos Pharma Ltd. (KAPA) to Dual List Shares on Upstream, Expanding Global Investor Access
Via Investor Brand Network
Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges
Via AB Newswire
Topics Initial Public Offering
Exposures Securities Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.